Safety and rapid response of dabrafenib and trametinib therapy during hyperbilirubinemia in metastatic melanoma

This case report describes the occurrence of hyperbilirubinemia as a complication of metastatic melanoma. A 72-year-old male patient was diagnosed with BRAF V600E-mutated melanoma with metastases in the liver, lymph nodes, lungs, pancreas, and stomach. Due to a lack of clinical data and specific gui...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in oncology 2023-02, Vol.13, p.1102330-1102330
Main Authors: Shalata, Walid, Steckbeck, Rachel, Polishchuk, Ilya, Cohen, Ahron Yehonatan, Rouvinov, Keren, Tokar, Margarita, Abu Jama, Ashraf, Abu Saleh, Omar, Sheva, Kim, Yakobson, Alexander
Format: Article
Language:English
Subjects:
BRAF mutation (V600E)
dabrafenib
hyperbilirubinemia
metastatic melanoma
Oncology
safety
trametinib
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This case report describes the occurrence of hyperbilirubinemia as a complication of metastatic melanoma. A 72-year-old male patient was diagnosed with BRAF V600E-mutated melanoma with metastases in the liver, lymph nodes, lungs, pancreas, and stomach. Due to a lack of clinical data and specific guidelines for the treatment of mutated metastatic melanoma patients with hyperbilirubinemia, a conference of specialists debated between initiating treatment or providing supportive care. Ultimately, the patient was started on the combination therapy of dabrafenib and trametinib. This treatment resulted in a significant therapeutic response normalization of bilirubin levels and an impressive radiological response of metastases just one month post-treatment initiation.
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2023.1102330